blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2785352

EP2785352 - STABLE INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN AND ALFAXALONE [Right-click to bookmark this link]
Former [2014/41]METHODS OF PRESERVING INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING A CYCLODEXTRIN AND A HYDROPHOBIC DRUG
[2019/36]
StatusNo opposition filed within time limit
Status updated on  15.01.2021
Database last updated on 03.10.2024
FormerThe patent has been granted
Status updated on  07.02.2020
FormerGrant of patent is intended
Status updated on  27.01.2020
FormerExamination is in progress
Status updated on  24.01.2020
FormerGrant of patent is intended
Status updated on  11.09.2019
FormerExamination is in progress
Status updated on  20.01.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Jurox Pty Ltd
85 Gardiner Street
Rutherford, NSW 2320 / AU
[2020/10]
Former [2014/41]For all designated states
Jurox Pty. Ltd.
85 Gardiners Road
Rutherford, NSW 2320 / AU
Inventor(s)01 / PASLOSKE, Kirby Shawn
18 Cascade Close
Louth Park, New South Wales 2320 / AU
02 / LAU, Kai
6 Pykett Place
Dural, New South Wales 2158 / AU
03 / RICHARDSON, Sarah Jane
97 Teralba Road
Adamstown, New South Wales 2289 / AU
04 / WILLIS, Amanda Aileen
3 Berwick Crescent
Maryland, New South Wales 2287 / AU
 [2014/41]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[N/P]
Former [2020/11]Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Former [2014/41]Oxley, Rachel Louise, et al
Mewburn Ellis LLP 33 Gutter Lane London
EC2V 8AS / GB
Application number, filing date12853138.127.11.2012
[2020/11]
WO2012AU01452
Priority number, dateAU2011090497029.11.2011         Original published format: AU 2011904970
AU2012090496209.11.2012         Original published format: AU 2012904962
[2014/41]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013078500
Date:06.06.2013
Language:EN
[2013/23]
Type: A1 Application with search report 
No.:EP2785352
Date:08.10.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 06.06.2013 takes the place of the publication of the European patent application.
[2014/41]
Type: B1 Patent specification 
No.:EP2785352
Date:11.03.2020
Language:EN
[2020/11]
Search report(s)International search report - published on:AU06.06.2013
(Supplementary) European search report - dispatched on:EP01.07.2015
ClassificationIPC:A61K31/57, A61K47/50, C08L5/16, A61P25/04, A61P29/00, A61P23/00, A61P43/00
[2019/36]
CPC:
C08L5/16 (EP,CN,KR,US); A61K47/40 (KR,US); A61K31/05 (EP,CN,KR,US);
A61K31/573 (KR,US); A61K31/14 (KR,US); A61K31/403 (EP,CN,KR,US);
A61K31/5415 (EP,CN,KR,US); A61K31/57 (EP,CN,US); A61K31/702 (KR);
A61K45/06 (EP,KR,US); A61K47/02 (KR,US); A61K47/10 (KR,US);
A61K47/6951 (EP,KR,US); A61K9/0019 (KR,US); A61K9/08 (KR);
A61P23/00 (EP,KR,US); A61P25/04 (EP,KR,US); A61P29/00 (EP,KR,US);
A61P43/00 (EP,KR,US); B82Y5/00 (EP,CN,KR,US); C08B37/0015 (EP,CN,KR,US) (-)
Former IPC [2015/31]A61K31/702, A61K47/48, C08L5/16
Former IPC [2014/41]A61K31/702, C08L5/16
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/41]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:STABILE INJIZIERBARE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ENTHALTEND 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN UND ALFAXALON[2019/36]
English:STABLE INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN AND ALFAXALONE[2019/36]
French:COMPOSITIONS PHARMACEUTIQUES INJECTABLES STABLES COMPRENANT DE LA 2-HYDROXYPROPYL-BETA-CYCLODEXTRINE ET DE L'ALFAXALONE[2019/36]
Former [2014/41]VERFAHREN ZUR KONSERVIERUNG INJIZIERBARER PHARMAZEUTISCHER ZUSAMMENSETZUNGEN MIT EINEM CYCLODEXTRIN UND EINEM HYDROPHOBEN WIRKSTOFF
Former [2014/41]METHODS OF PRESERVING INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING A CYCLODEXTRIN AND A HYDROPHOBIC DRUG
Former [2014/41]PROCÉDÉS DE CONSERVATION DE COMPOSITIONS PHARMACEUTIQUES INJECTABLES COMPRENANT UNE CYCLODEXTRINE ET UN MÉDICAMENT HYDROPHOBE
Entry into regional phase20.05.2014National basic fee paid 
20.05.2014Search fee paid 
20.05.2014Designation fee(s) paid 
20.05.2014Examination fee paid 
Examination procedure30.07.2013Request for preliminary examination filed
International Preliminary Examining Authority: AU
20.05.2014Examination requested  [2014/41]
25.01.2016Amendment by applicant (claims and/or description)
23.01.2017Despatch of a communication from the examining division (Time limit: M06)
28.07.2017Reply to a communication from the examining division
05.03.2018Despatch of a communication from the examining division (Time limit: M06)
10.09.2018Reply to a communication from the examining division
14.12.2018Despatch of a communication from the examining division (Time limit: M04)
09.04.2019Reply to a communication from the examining division
12.09.2019Communication of intention to grant the patent
21.01.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
21.01.2020Fee for grant paid
21.01.2020Fee for publishing/printing paid
27.01.2020Information about intention to grant a patent
27.01.2020Receipt of the translation of the claim(s)
Divisional application(s)EP18198778.5  / EP3446692
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  23.01.2017
Opposition(s)14.12.2020No opposition filed within time limit [2021/07]
Fees paidRenewal fee
11.12.2014Renewal fee patent year 03
10.11.2015Renewal fee patent year 04
10.11.2016Renewal fee patent year 05
13.11.2017Renewal fee patent year 06
14.11.2018Renewal fee patent year 07
14.11.2019Renewal fee patent year 08
Penalty fee
Additional fee for renewal fee
30.11.201403   M06   Fee paid on   11.12.2014
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU27.11.2012
AL11.03.2020
CY11.03.2020
EE11.03.2020
LT11.03.2020
LV11.03.2020
MK11.03.2020
MT11.03.2020
PL11.03.2020
RO11.03.2020
RS11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
TR11.03.2020
BG11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
LU27.11.2020
[2022/31]
Former [2022/30]HU27.11.2012
AL11.03.2020
CY11.03.2020
EE11.03.2020
LT11.03.2020
LV11.03.2020
MT11.03.2020
PL11.03.2020
RO11.03.2020
RS11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
TR11.03.2020
BG11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
LU27.11.2020
Former [2022/27]HU27.11.2012
CY11.03.2020
EE11.03.2020
LT11.03.2020
LV11.03.2020
MT11.03.2020
PL11.03.2020
RO11.03.2020
RS11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
TR11.03.2020
BG11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
LU27.11.2020
Former [2022/26]EE11.03.2020
LT11.03.2020
LV11.03.2020
PL11.03.2020
RO11.03.2020
RS11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
TR11.03.2020
BG11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
LU27.11.2020
Former [2021/33]EE11.03.2020
LT11.03.2020
LV11.03.2020
PL11.03.2020
RO11.03.2020
RS11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
LU27.11.2020
Former [2021/13]EE11.03.2020
LT11.03.2020
LV11.03.2020
PL11.03.2020
RO11.03.2020
RS11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
Former [2020/50]EE11.03.2020
LT11.03.2020
LV11.03.2020
RO11.03.2020
RS11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
Former [2020/49]LT11.03.2020
LV11.03.2020
RO11.03.2020
RS11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
Former [2020/48]LT11.03.2020
LV11.03.2020
RO11.03.2020
RS11.03.2020
SM11.03.2020
BG11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
Former [2020/47]LT11.03.2020
LV11.03.2020
RS11.03.2020
BG11.06.2020
GR12.06.2020
IS11.07.2020
Former [2020/46]LV11.03.2020
RS11.03.2020
BG11.06.2020
GR12.06.2020
IS11.07.2020
Former [2020/39]LV11.03.2020
RS11.03.2020
BG11.06.2020
GR12.06.2020
Former [2020/38]LV11.03.2020
RS11.03.2020
GR12.06.2020
Former [2020/37]LV11.03.2020
RS11.03.2020
Documents cited:Search[XI]EP0605203  (SENJU PHARMA CO [JP]);
 [XI]WO9632135  (FARMARC NEDERLAND BV OF CITCO [NL], et al);
 [XI]WO9710805  (CIBA GEIGY AG [CH], et al);
 [XDI]WO2005082416  (PFIZER PROD INC [US], et al);
International search[X]WO0197796  (BHARAT SERUMS & VACCINES LTD [IN], et al);
 [A]US2007155697  (ADAMI ROGER C [US], et al);
by applicantEP0605203
 WO9632135
 WO9710805
 WO0170234
 US6358935
 US6723353
 WO2005082416
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.